Erratum: A dose and time response Markov model for the in-host dynamics of infection with intracellular bacteria following inhalation: With application to Francisella tularensis (Journal of the Royal Society Interface (2014) 11 (20140119) DOI: 10.1098/rsif.2014.0119);A dose and time response Markov model for the in-host dynamics of infection with intracellular bacteria following inhalation: With application to Francisella tularensis

Journal of the Royal Society Interface

Volumn 11, Issue 95, 2014, Pages

  Wood, R M ^a   Egan, J R ^a   Hall, I M ^a  

^a PUBLIC HEALTH ENGLAND   (United Kingdom)

Author keywords

Dose response relationship; Francisella tularensis; In host mechanistic model; Infectious disease incubation period; Markov process; Systems biology

Indexed keywords

ANTIGEN-ANTIBODY REACTIONS; BACTERIA; MARKOV PROCESSES; STOCHASTIC SYSTEMS;

DOSE RESPONSE RELATIONSHIPS; FRANCISELLA TULARENSIS; INCUBATION PERIODS; MECHANISTIC MODELING; SYSTEMS BIOLOGY;

STOCHASTIC MODELS;

ARTICLE; BACTERIAL GROWTH; BACTERIAL STRAIN; BACTERIAL VIRULENCE; CELL FUNCTION; CONTROLLED STUDY; DOSE RESPONSE; FRANCISELLA TULARENSIS; HOST PATHOGEN INTERACTION; HUMAN; HUMAN CELL; IMMUNE SYSTEM; IN VITRO STUDY; IN VIVO STUDY; INCUBATION TIME; INHALATION; MATHEMATICAL MODEL; PHAGOCYTE; PHAGOCYTOSIS; POPULATION DISTRIBUTION; POPULATION DYNAMICS; PROBABILITY; SURVIVAL RATE; TULAREMIA; ANIMAL; BIOLOGICAL MODEL; METABOLISM; PATHOGENICITY; PATHOPHYSIOLOGY;

ANIMALS; FRANCISELLA TULARENSIS; HUMANS; MARKOV CHAINS; MODELS, BIOLOGICAL; TULAREMIA;

EID: 84901402025     PISSN: 17425689     EISSN: 17425662     Source Type: Journal    
DOI: 10.1098/rsif.2020.0189     Document Type: Erratum

References (58)

1. Irwin JO. 1937 Statistical method applied to biological assays. Suppl. J. R. Stat. Soc. 4, 1-60. (doi:10.2307/2984120)
2. Gaddum JH. 1945 Lognormal distributions. Nature 156, 463-466. (doi:10.1038/156463a0)
3. Jones RM, Nicas M, Hubbard A, Sylvester MD, Reingold A. 2005 The infectious dose of Francisella tularensis (Tularemia). Appl. Biosafety 10, 227-239.
4. Meynell GG, Stocker BAD. 1957 Some hypotheses on the aetiology of fatal infections in partially resistant hosts and their application to mice challenged with Salmonella paratyphi-B or Salmonella typhimurium by intraperitoneal injection. J. Gen. Microbiol. 16, 38-58. (doi:10.1099/00221287-16-1-38)
5. Armitage P, Meynell GG, Williams T. 1965 Birth-death and other models for microbial infection. See http://www.nature.com/nature/journal/v207/n4997/abs/ 207570a0.html (accessed 15 December 2013).
6. Brookmeyer R, Johnson E, Barry S. 2003 Modeling the incubation period of anthrax. Stat. Med. 24, 531-542. (doi:10.1002/sim.2033)
7. Huang Y, Haas CN. 2011 Quantification of the relationship between bacterial kinetics and host response for monkeys exposed to aerosolized Francisella tularensis. Appl. Environ. Microbiol. 77, 485-490. (doi:10.1128/AEM.01190-10)
8. Medley GF, Anderson RM, Cox DR, Billard L. 1987 Incubation period of AIDS in patients infected via blood transfusion. See http://www.nature.com/nature/ journal/v328/n6132/abs/328719a0.html (accessed 15 December 2013).
9. D' Aignaux JH et al. 1999 Incubation period of Creutzfeldt-Jakob disease in human growth hormone recipients in France. Neurology 53, 1197-1201. (doi:10.1212/WNL.53.6.1197)
10. Farewell VT, Herzberg AM, James KW, Ho LM, Leung GM. 2005 SARS incubation and quarantine times: when is an exposed individual known to be disease free? Stat. Med. 24, 3431-3445. (doi:10.1002/sim.2206)
11. Egan JR, Hall IM, Lemon DJ, Leach S. 2011 Modeling Legionnaires' disease outbreaks: estimating the timing of an aerosolized release using symptom-onset dates. Epidemiology 22, 188-198. (doi:10.1097/EDE.0b013e31820937c6)
12. Meynell GG, Meynell EW. 1958 The growth of micro-organisms in vivo with particular reference to the relation between dose and latent period. J. Hyg. 56, 323-346. (doi:10.1017/S0022172400037827)
13. Egan JR, Hall IM, Leach S. 2011 Modeling inhalational tularemia: deliberate release and public health response. Biosecur. Bioterror. 9, 331-343. (doi:10.1089/bsp.2011.0004)
14. Saaty TL. 1961 Some stochastic processes with absorbing barriers. J. R. Stat. Soc. B (Methodol.) 23, 319-334.
15. Shortley G. 1965 A stochastic model for distributions of biological response times. Biometrics 21, 562-582. (doi:10.2307/2528542)
16. Silva MT. 2012 Classical labeling of bacterial pathogens according to their lifestyle in the host: inconsistencies and alternatives. Front. Microbiol. 3, 71. (doi:10.3389/fmicb.2012.00071)
17. Dennis DT et al. 2001 Tularemia as a biological weapon. J. Am. Med. Assoc. 285, 2763-2773. (doi:10.1001/jama.285.21.2763)
18. CDC. 2013 Bioterrorism agents/diseases by category. See http://www.bt.cdc.gov/agent/agentlist-category.asp (accessed 15 December 2013).
19. Parmely MJ, Fischer JL, Pinson DM. 2009 Programmed cell death and the pathogenesis of tissue injury induced by type A Francisella tularensis. FEMS Microbiol. Lett. 301, 1-11. (doi:10.1111/j.1574-6968.2009.01791.x)
20. Eigelsbach HT, Braun W, Herring RD. 1951 Studies on the variation of Bacterium tularense. J. Bacteriol. 61, 557-569.
21. Larsson P et al. 2005 The complete genome sequence of Francisella tularensis, the causative agent of tularemia. Nat. Genet. 37, 153-159. (doi:10.1038/ng1499)
22. Ellis J, Oyston PCF, Green M, Titball RW. 2002 Tularemia. Clin. Microbiol. Rev. 15, 631-646. (doi:10.1128/CMR.15.4.631-646.2002)
23. Shortley G, Wilkins JR. 1965 Independent-action and birth-death models in experimental microbiology. Bacteriol. Rev. 29, 102-141.
24. Wilkening DA. 2008 Modeling the incubation period of inhalational anthrax. Med. Decision Making 28, 593-605. (doi:10.1177/0272989X08315245)
25. Newman MC, McCloskey JT. 2000 The individual tolerance concept is not the sole explanation for the probit dose-effect model. Environ. Toxicol. Chem. 19, 520-526. (doi:10.1002/etc.5620190235)
26. Zhao Y, Newman MC. 2007 The theory underlying dose-response models influences predictions for intermittent exposures. Environ. Toxicol. Chem. 26, 543-547. (doi:10.1897/06-398R.1)
27. Oyston PC, Sjöstedt A, Titball RW. 2004 Tularaemia: bioterrorism defence renews interest in Francisella tularensis. Nat. Rev. Microbiol. 2, 967-978. (doi:10.1038/nrmicro1045)
28. Lindemann SR et al. 2011 Francisella tularensis Schu S4 O-antigen and capsule biosynthesis gene mutants induce early cell death in human macrophages. Infect. Immun. 79, 581-594. (doi:10.1128/IAI.00863-10)
29. Oyston PC. 2008 Francisella tularensis: unravelling the secrets of an intracellular pathogen. J. Med. Microbiol. 57, 921-930. (doi:10.1099/jmm.0.2008/ 000653-0)
30. Eigelsbach HT, Tulis JJ, McGavran MH, White JD. 1962 Live tularemia vaccine I. Host-parasite relationship in monkeys vaccinated intracutaneously or aerogenically. J. Bacteriol. 84, 1020-1027.
31. White JD, Rooney JR, Prickett PA, Derrenbacher EB, Beard CW, Griffith WR. 1964 Pathogenesis of experimental respiratory tularemia in monkeys. J. Infect. Dis. 114, 277-283. (doi:10.1093/infdis/114.3.277)
32. Saslaw S, Eigelsbach HT, Prior JA, Wilson HE, Carhart S. 1961 Tularemia vaccine study II. Respiratory challenge. Arch. Intern. Med. 107, 702-714. (doi:10.1001/archinte.1961.03620050068007)
33. Sawyer WD, Dangerfield HG, Hogge AL, Crozier D. 1966 Antibiotic prophylaxis and therapy of airborne tularemia. Bacteriol. Rev. 30, 542-550.
34. Clemens DL, Lee B-Y, Horwitz MA. 2004 Virulent and avirulent strains of Francisella tularensis prevent acidification and maturation of their phagosomes and escape into the cytoplasm in human macrophages. Infect. Immun. 72, 3204-3217. (doi:10.1128/IAI.72.6.3204-3217.2004)
35. Löfgren S, Tärnvik A, Bloom GD, Sjöberg W. 1983 Phagocytosis and killing of Francisella tularensis by human polymorphonuclear leukocytes. Infect. Immun. 39, 715-720. (Pubitemid 13188350)
36. Geier H, Celli J. 2011 Phagocytic receptors dictate phagosomal escape and intracellular proliferation of Francisella tularensis. Infect. Immun. 79, 2204-2214. (doi:10.1128/IAI.01382-10)
37. Elkins KL, Cowley SC, Bosio CM. 2003 Innate and adaptive immune responses to an intracellular bacterium, Francisella tularensis live vaccine strain. Microbes Infect. 5, 135-142. (doi:10.1016/S1286-4579(02)00084-9)
38. Crane DD, Warner SL, Bosio CM. 2009 A novel role for plasmin-mediated degradation of opsonizing antibody in the evasion of host immunity by virulent, but not attenuated, Francisella tularensis. J. Immunol. 183, 4593-4600. (doi:10.4049/jimmunol.0901655)
39. Wilson JE, Katkere B, Drake JR. 2009 Francisella tularensis induces ubiquitin-dependent major histocompatibility complex class II degradation in activated macrophages. Infect. Immun. 77, 4953-4965. (doi:10.1128/IAI.00844-09)
40. Schricker RL, Eigelsbach HT, Mitten JQ, Hall WC. 1972 Pathogenesis of tularemia in monkeys aerogenically exposed to Francisella tularensis 425. Infect. Immun. 5, 734-744.
41. McCrumb Jr FR. 1961 Aerosol infection of man with Pasteurella tularensis. Bacteriol. Rev. 25, 262-267.
42. Sawyer WD et al. 1966 Effect of aerosol age on the infectivity of airborne Pasteurella tularensis for Macaca mulatta and man. J. Bacteriol. 91, 2180-2184.
43. Hornick RB, Eigelsbach HT. 1966 Aerogenic immunization of man with live tularemia vaccine. Bacteriol. Rev. 30, 532-538.
44. Alluisi EA, Beisel WR, Bartelloni PJ, Coates GD. 1973 Behavioral effects of tularemia and sandfly fever in man. J. Infect. Dis. 128, 710-717. (doi:10.1093/infdis/128.6.710)
45. Brookmeyer R, Gail MH. 1988 A method for obtaining short-term projections and lower bounds on the size of the AIDS epidemic. J. Am. Stat. Assoc. 83, 301-308. (doi:10.1080/01621459.1988.10478599)
46. Becker NG, Watson LF, Carlin JB. 1991 A method of non-parametric back-projection and its application to aids data. Stat. Med. 10, 1527-1542. (doi:10.1002/sim.4780101005)
47. Legrand J, Egan JR, Hall IM, Cauchemez S, Leach S, Ferguson NM. 2009 Estimating the location and spatial extent of a covert anthrax release. PLoS Comput. Biol. 5, e1000356. (doi:10.1371/journal.pcbi.1000356)
48. Williams T. 1965 The basic birth-death model for microbial infections. J. R. Stat. Soc. B 27, 338-360.
49. Othmer HG, Dunbar SR, Alt W. 1988 Models of dispersal in biological systems. J. Math. Biol. 26, 263-298. (doi:10.1007/BF00277392)
50. Tokarski C et al. 2012 Agent-based modeling approach of immune defense against spores of opportunistic human pathogenic fungi. Front. Microbiol. 3, 129. (doi:10.3389/fmicb.2012.00129)
51. Day WC, Berendt RF. 1972 Experimental tularemia in Macaca mulatta: relationship of aerosol particle size to the infectivity of airborne Pasteurella tularensis. Infect. Immun. 5, 77-82.
52. Golovliov I, Baranov V, Krocova Z, Kovarova H, Sjöstedt A. 2003 An attenuated strain of the facultative intracellular bacterium Francisella tularensis can escape the phagosome of monocytic cells. Infect. Immun. 71, 5940-5950. (doi:10.1128/IAI.71.10.5940-5950.2003)
53. Mack K, Fulop M, Manchee RJ, Stirling CJ. 1994 A new cell assay to determine the virulence of Francisella tularensis. Lett. Appl. Microbiol. 19, 158-160. (doi:10.1111/j.1472-765X.1994.tb00931.x)
54. Butchar JP et al. 2007 Francisella tularensis induces IL-23 production in human monocytes. J. Immunol. 178, 4445-4454. (Pubitemid 46492396)
55. Santic M, Molmeret M, Klose KE, Jones S, Kwaik YA. 2005 The Francisella tularensis pathogenicity island protein IglC and its regulator MglA are essential for modulating phagosome biogenesis and subsequent bacterial escape into the cytoplasm. Cell. Microbiol. 7, 969-979. (doi:10.1111/j.1462-5822.2005. 00526.x)
56. Holcomb DL, Smith MA, Ware GO, Hung Y-C, Brackett RE, Doyle MP. 1999 Comparison of six dose-response models for use with food-borne pathogens. Risk Anal. 19, 1091-1100. (doi:10.1111/j.1539-6924.1999.tb01130.x)
57. Sartwell PE. 1950 The distribution of incubation periods of infectious disease. Am. J. Epidemiol. 51, 310-318.
58. Nishiura H. 2007 Early efforts in modeling the incubation period of infectious diseases with an acute course of illness. Emerg. Themes Epidemiol. 4, 2. (doi:10.1186/1742-7622-4-2)